FccRIIa-mediated thrombocytopenia is associated with drug-dependent antibodies (DDAbs). We investigated the correlation between a IIb b 3 binding epitopes and induction of DDAbs. An FccRIIa-transgenic mouse model was used to evaluate thrombocytopenia among anti-thrombotics. An antithrombotic with binding motif toward a IIb bpropeller domain has less bleeding tendency.
Summary. Background: Thrombocytopenia, a common side effect of Arg-Gly-Asp-mimetic antiplatelet drugs, is associated with drug-dependent antibodies (DDAbs) that recognize conformation-altered integrin a IIb b 3 . Objective: To explore the correlation between a IIb b 3 binding epitopes and induction of DDAb binding to conformation-altered a IIb b 3 , we examined whether two purified disintegrins, TMV-2 and TMV-7, with distinct binding motifs have different effects on induction of a IIb b 3 conformational change and platelet aggregation in the presence of AP2, an IgG 1 inhibitory mAb raised against a IIb b 3 . Methods: We investigated the possible mechanisms of intrinsic platelet activation of TMV-2 and TMV-7 in the presence of AP2 by examining the signal cascade, tail bleeding time and immune thrombocytopenia in Fc receptor c-chain IIa (FccRIIa) transgenic mice. Results: TMV-7 has a binding motif that recognizes the a IIb b-propeller domain of a IIb b 3 , unlike that of TMV-2. TMV-7 neither primed the platelets to bind ligand, nor caused a conformational change of a IIb b 3 as identified with the ligand-induced binding site mAb AP5. In contrast to eptifibatide and TMV-2,
Introduction
Disintegrins, which are low molecular weight and cysteine-rich venom proteins containing an Arg-Gly-Asp (RGD) or Lys-Gly-Asp loop, were originally known as a IIb b 3 antagonists, and are potential antithrombotic agents [1] [2] [3] . RGD-mimetic drugs such as eptifibatide and tirofiban represent major advances in the treatment of acute coronary syndromes [4] . However, side effects, including life-threatening thrombocytopenia and bleeding, have limited their use in patients undergoing percutaneous coronary intervention and stenting [5] [6] [7] . Thus, the search to identify ideal antithrombotic agents that have minimal bleeding side effects continues.
Thrombocytopenia after exposure to RGD-mimetic drugs is linked to ligand-induced conformational change and the subsequent emergence of ligand-induced binding sites (LIBSs) [8] , which are recognized by drug-dependent antibodies (DDAbs) [9] . The naturally occurring DDAb engages the integrin b 3 subunit such that Fc receptor c-chain IIa (FccRIIa) (i.e. CD32), an Fc receptor for IgG expressed on platelets, and its downstream signal molecules become activated, resulting in platelet clearance and thrombocytopenia [10] [11] [12] .
We previously reported that RGD-containing disintegrins (e.g. rhodostomin and accutin) in combination with AP2, an inhibitory IgG 1 mAb raised against a IIb b 3 , competed with mAb 7E3 for binding of activated human platelets [10] . Related reports also indicated that eptifibatide-dependent, antibody-mediated platelet aggregation was induced in the presence of patient serum plus eptifibatide plus AP2 [11, 13] , demonstrating that patient antibodies bridging a IIb b 3 and FccRIIa induce platelet aggregation in an a IIb b 3 -independent manner. Here, we found that, in contrast to a IIb b 3 antagonists with higher bleeding risk (i.e. eptifibatide, the RGD-containing disintegrin rhodostomin [10, 14] , and TMV-2), the purified RGD-containing disintegrin TMV-7 from the snake venom of Trimeresurus mucrosquamatus, which has a binding motif different from that of rhodostomin and TMV-2, potently inhibits platelet aggregation and thrombosis in vivo without causing a drug-induced conformational change in a IIb b 3 and FccRIIa-mediated thrombocytopenia. Further exploration of the differences between the molecular interactions of a IIb b 3 and the disintegrins may provide valuable information for the development of a new generation of a IIb b 3 antagonists as efficacious antithrombotics with a better safety profile, i.e. without causing thrombocytopenia and bleeding.
Materials and methods

Materials
Anti-a IIb b 3 antibody 2905C10 (MA1-21188) was from Thermo Fisher (Ave Waltham, MA, USA). Alexa 488-conjugated fibrinogen (F13191) was from Invitrogen (Carslbad, CA, USA). Anti-FccRIIa mAb (sc-13527) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PAC1 antibody (340507) was from BD Biosciences (Franklin Lakes, NJ, USA). Anti-integrin b 3 antibody (CBL479) was from Millipore (Billerica, MA, USA).
Expression and purification of trimucrin and its mutants
The expression of trimucrin/TMV-7 and its nine mutants (K41I/K42E/K43E/R44G/R51K, K41I/K42E/K43E/R44G/ R51K/G70S, N54W/P55N, N54W/P55N/G70R, N54W/ P55N/G70R/L71F/Y72H, K41M/R44G/N54W/P55N, K41M/R44G/N54W/P55N/G70R/L71F/Y72H, N54F/ G70R/L71F/Y72H, and N54F) in Pichia pastoris was accomplished with previously described protocols [15, 16] .
Preparation of human platelet-rich plasma (PRP) and platelet suspension (PS) Blood was collected from healthy volunteers who had not taken any medication for 2 weeks prior to the study. All participants provided informed consent, and this study was approved by the institutional review board of National Taiwan University Hospital. Preparation of human PRP and PS was performed as described previously [10] .
Western blotting and immunoprecipitation
Washed platelets were treated with agents, and lysed with RIPA buffer, which enables extraction and measurement of cytoplasmic proteins. Cell lysates were immunoprecipitated with anti-b 3 (i.e. CD61), and then incubated with Protein A/G sepharose beads. Thereafter, immunoprecipitation and western blotting were performed as described previously [10, 17] .
Binding assays of cotreatment of disintegrins with mAbs
PSs were incubated with agents, and then labeled with the primary mAbs 7E3, 10E5, AP2 or AP5 at room temperature for 30 min. Labeled cells were incubated with FITC-conjugated goat anti-mouse IgG at room temperature for 30 min, and analyzed with a FACS Calibur.
Priming assay
For the priming assay, detection was performed with Alexa 488-conjugated fibrinogen or FITC-labeled PAC1 antibody, and the assay was performed as described previously [18, 19] .
Rotational thromboelastometry (ROTEM)
Human whole blood was collected from healthy donors, and analyzed with the ROTEM delta system as described previously [20] . Briefly, whole blood was treated with agents at 37°C, and then recalcified with star-TEM reagent (0.2 M CaCl 2 ) to initiate the INTEM assay.
Measurement of procoagulant activity
Procoagulant activity was measured with the plasma recalcification time (RT) assay [21] . In brief, PRP was incubated with either agent for 10 min at 37°C, prewarmed 12 mM CaCl 2 was then added to initiate clotting, and the plasma clotting time (CT) was recorded.
Clot retraction
Clot retraction was measured with a method described previously [22, 23] .
Tg [FCGR2A]11Mkz/J) were generated in the laboratory of S.E.M. [24] and obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Mouse genotypes were confirmed by use of The Jackson Laboratory-defined PCR protocol, and used for experiments when the mice were aged 8-20 weeks. All procedures were approved by the Laboratory Animal Care and Use Committee of the College of Medicine, National Taiwan University.
Fluorescent dye-induced platelet thrombus formation in mesenteric venules of mice A modification of a previously described method was used [25] . Briefly, fluorescein sodium (12.5 mg kg
À1
) was administered intravenously through a lateral tail vein for 5 min. After intravenous injection with agents, the microvascular bed was observed with an Olympus IX71 inverted phase/fluorescence microscope (Olympus Corporation, Tokyo, Japan).
FeCl 3 -induced arterial thrombosis model
A modification of a previously described method was used [14] . Briefly, a 2-mm section of the carotid artery of an anesthetized mouse was exposed, agents were intravenously administered to mice for 5 min, and thrombosis was induced by applying filter paper saturated with 7.5% FeCl 3 solutions on the carotid adventitia. After 3 min of exposure, the filter paper was removed, and blood flow was monitored with a microvascular probe for 80 min.
Tail bleeding time
Bleeding times were measured as described previously [26] , and recorded for a maximum of 10 min. The endpoint was the cessation of bleeding [27] .
Safety index calculation
The safety index is defined as the ratio between the concentration of disintegrin needed to induce platelet activation in the presence of AP2, an inhibitory mAb raised against a IIb b 3 , and the IC 50 for collagen-induced platelet aggregation.
Pharmacokinetic studies
Agents were were intravenously administered to male ICR mice. Blood was obtained via the vena cava. Citrated PRP was prepared by centrifugation at 200 9 g for 4 min, and the functional half-life was determined with the platelet aggregation assay as described above [14] .
Statistical analysis
Results are expressed as mean AE standard error of the mean. Statistical analysis was performed with one-way ANOVA and the Newman-Keuls multiple comparison test. P < 0.05 was considered to indicate a significant difference.
Results
Purification of TMV-2 and TMV-7
The crude venom of T. mucrosquamatus (i.e. Protobothrops mucrosquamatus) was fractionated by ion exchange (Fig. S1A) , and fraction 2 and fraction 7 with platelet inhibitory activity were applied to a Sephadex G-75 column for further purification (Fig. S1B) . Antiplatelet fraction 2-iii (Fig. S1B, left) and fraction 7-ii (Fig. S1B , right) were collected. Fraction 7-ii was further refractionated on a fast protein liquid chromatography column, and antiplatelet fraction b was collected (Fig. S1C) . Fraction 2-iii and fraction 7-ii-b were purified on a reversephase HPLC C18 column (Fig. S1D,E) . Finally, these two purified proteins were lyophilized and named TMV-2 and TMV-7. The purified TMV-2 and TMV-7 were shown to be single-chain peptides by SDS-PAGE, as their mobility was the same in the presence or absence of 2% b-mercaptoethanol (Fig. 1A) .
Characterization of TMV-2 and TMV-7
To investigate the sequences of TMV-2 and TMV-7, both top-down and bottom-up approaches with liquid chromatography (LC)-tandem mass spectrometry (MS/MS) were applied [28, 29] . In this study, reduced protein molecules were analyzed with LC-MS to obtain their molecular masses, which were 7493.1760 Da and 7669.3047 Da for TMV-2 (Fig. 1B, left) and TMV-7 (Fig. 1B, right) , respectively. Higher-energy collisional dissociation fragmentation was further applied to TMV-2 ( Fig. S2A ) and TMV-7 ( Fig. S2B ) to generate the MS/MS spectra, which were used to confirm their C-terminal terminal sequences (Fig. 1C, bold print) . The results derived from the bottom-up approach with LC-MS/MS provided information on the sequence near the protein N-terminus. As shown in the gray area of Fig. 1C , the partial sequence of TMV-2 had 76% sequence identity with the mature chain (residues 409-479) of the zinc metalloproteinase/disintegrin PMMP-1 (taxonomic identifier 103944; upper panel of Fig. 1C) , and the partial sequence of TMV-7 had 95% sequence identity with trimucrin [30] (lower panel of Fig. 1C ). The expression of TMV-7 in P. pastoris was accomplished as previously described [15, 16] , and the protein was further purified on a reverse-phase C18 HPLC column. The recombinant TMV-7 was > 95% pure as judged by SDS-PAGE results.
TMV-7 shows 81%, 72% and 65% identity with TMV-2, rhodostomin [31] , and trigramin [1] , which contain the RGD sequence (residues 51-53) near their C-terminal ends (Fig. 1D) , and its properties were compared with those of TMV-2, rhodotomin and eptifibatide in this study. The tripeptide within the molecule is essential for mediating the binding of a IIb b 3 .
TMV-2 and TMV-7 inhibit agonist-induced human platelet aggregation through a IIb b 3 receptor blockade Both TMV-2 and TMV-7 concentration-dependently blocked the platelet aggregation caused by collagen (10 lg mL À1 ) or ADP (20 lM) in PRP ( Fig. 2A,B) , and by collagen (10 lg mL À1 ) or thrombin (0.1 U mL
À1
) in PSs (Fig. 2C,D) . In addition, TMV-2 and TMV-7 apparently did not affect the initial platelet shape change (reflected by the initial decrease in transmission) caused by these inducers in human platelets.
We explored which platelet membrane receptors were responsible for TMV-2 and TMV-7 binding by using flow cytometry with specific mAbs. As shown in Fig. 3A , TMV-2 and TMV-7 significantly reduced the binding of mAb 290.5C10 to the a IIb b 3 complex, but they had no inhibitory effect on the binding of mAbs raised against glycoprotein (GP) VI or GPIb. Under the experimental conditions used, TMV-2 ( binding to platelets in a concentration-dependent manner. These results clearly indicate that TMV-2 and TMV-7 specifically inhibit human platelet aggregation through a IIb b 3 receptor blockade.
TMV-7 binds to the a IIb b-propeller of a IIb b 3 differently from TMV-2
We used mAbs (i.e. 7E3 and 10E5) raised against a IIb b 3 as competitive probes to identify the binding motifs of TMV-2 and TMV-7 on the platelet a IIb b 3 receptor (Fig. 3C,D) . It has been reported that 7E3 interacts with the bA (I-like) domains [32, 33] and shares the same binding site with rhodostomin and trigramin [10, 23, 34, 35] ; the 10E5 binding site is close to the cap subdomain of the a IIb b-propeller [8] . As shown in Fig. 3C ,D, both rhodostomin and TMV-2 competitively inhibited 7E3 binding to a IIb b 3 . In contrast, TMV-7 had no effect on 7E3 binding, but competitively reduced 10E5 binding to platelets. These results demonstrate that the binding site of rhodostomin and TMV-2 is close to the bA domains, whereas the binding site of TMV-7 is near to the a IIb b-propeller domain.
TMV-7 does not prime platelets to bind ligands or cause a conformational change in a IIb b 3 identified by the LIBS antibody AP5 and mAb AP2
It is well established that the RGD recognition site of a IIb b 3 is available to macromolecules that contain RGD even on non-activated platelets, provided that the affinity of the ligand is adequate [36] . Eptifibatide, an RGD mimetic, induces a conformation change of a IIb b 3 and enhances the ligand binding affinity for a IIb b 3 [8, 37] . Thus, we investigated the priming effect of a IIb b 3 among the RGD-containing disintegrins rhodostomin, TMV-2 and TMV-7 by analyzing their ability to adopt a high-affinity ligand (i.e. fibrinogen and PAC-1) binding conformation. As shown in Fig. 4A -C, eptifibatide, rhodostomin and TMV-2 significantly increased fibrinogen (Fig. 4A ) or PAC-1 (Fig. 4B) binding to a IIb b 3 , whereas TMV-7 did not prime ligand binding as compared with resting platelets.
Given that the conformational change in a IIb b 3 after exposure to RGD-mimetic drugs causes exposure of cryptic epitopes, we used the LIBS antibody AP5 raised against conformation-dependent epitopes (Fig. 4D) or the mAb AP2 raised against a IIb b 3 [38] (Fig. 4E ) as a platform for evaluating the adverse reactions following administration of a IIb b 3 antagonists. After treatment with eptifibatide, rhodostomin, and TMV-2, the level of AP5 or AP2 binding to a IIb b 3 increased by 1.5-fold to five-fold over that in resting platelets, whereas TMV-7 did not enhance AP5 and AP2 binding to a IIb b 3 as compared with resting platelets.
Different effects of TMV-2 or TMV-7 in combination with AP2 mAb on induction of platelet aggregation
A recent report showed that eptifibatide-induced thrombocytopenia was associated with an increase in the level of circulating procoagulant platelet-derived microparticles [39] . We previously reported that the combination of a disintegrin (e.g. rhodostomin or accutin) with AP2 causes platelet aggregation [10] . Here, we found that eptifibatide and TMV-2 also showed similar activating effects when combined with AP2 ( Fig. 5A) , whereas the combination of TMV-7 and AP2 did not induce platelet aggregation (right panel of Fig. 5A ), even at a high concentration (10 lg mL À1 ; data not shown).
The fact that ETDA and indomethacin (cyclooxygenase inhibitor) completely inhibited the platelet aggregation caused by the combination of TMV-2 and AP2 (Fig. 5B) suggests that extracellular Ca 2+ and endogenous activation of phospholipase (PLC) A2 were essential for this activation process.
Combination of TMV-7 with AP2 does not induce FccRIIamediated platelet aggregation and the downstream ITAMSyk-PLCc2 pathway FccRIIa has been identified as an ITAM-bearing transmembrane receptor responsible for mediating 'outside-in' signaling through a IIb b 3 [12] . Here, we pretreated platelets with an anti-FccRIIa mAb (i.e. CD32) prior to treatment with TMV-2 and AP2, and found that platelet aggregation (right panel of Fig. 5B ) and the ITAM-Syk-PLCc2 pathway (Fig. 5C) were blocked, indicating that FccRIIa is essential for triggering platelet activation.
We previously reported that accutin/AP2 and rhodostomin/AP2 caused tyrosine phosphorylation of the ITAM-Syk-PLCc2 pathway employed by FccRIIa [10] . As shown in the left panel of Fig. 5C , TMV-2/AP2-treated platelets also showed time-dependent tyrosine phosphorylation of FAK, Src, Syk, phosphoinositide 3-kinase, and PLCc2 (Fig. 5C) . We further confirmed these phenomena by immunoprecipitating the lysed platelets with (Fig. 5D ) and phosphorylation ( Fig. 5E ) of FccRIIa and its downstream molecules, whereas TMV-7/AP2 did not (Fig. S3) , indicating that TMV-7 binding to the a IIb b-propeller neither causes recruitment of AP2 by engaging with the bA domains of b 3 and FccRIIa (illustrated schematically in Fig. 5F ), nor leads to transactivation of integrin-associated and Fc receptor-associated protein tyrosine kinases, which function as ITAM kinases that initiate platelet activation [40] .
TMV-7 inhibits platelet aggregation ex vivo and thrombotic occlusion in vivo
In a mouse model, intravenous injection of 0.25 lg g À1 TMV-2 and TMV-7 potently inhibited platelet aggregation of PRP caused by collagen, a protease-activated receptor-4 agonist and ADP ex vivo (Fig. 6A-C) . Furthermore, TMV-2 (0.25 lg g À1 and 0.5 lg g À1 ), TMV-7 (0.25 lg g À1 and 0.5 lg g
À1
) or eptifibatide (0.18 lg g À1 ) efficaciously increased the occlusion time of illuminated mesenteric venules (Fig. 6D) . In the FeCl 3 -induced arterial thrombosis model, complete carotid artery occlusion occurred in control ICR mice in response to 7.5% FeCl 3 within 10 min, whereas the time needed for FeCl 3 -induced thrombus formation was increased to > 80 min by 0.25 lg g À1 TMV-2 and TMV-7 (Fig. 6E,F) .
TMV-7 does not prolong tail bleeding time
Next, we used a mouse tail-transection model to evaluate the influence of TMV-2 and TMV-7 on physiologic hemostasis. As shown in Fig. 6G , eptifibatide, TMV-2, and rhodostominin, in contrast to TMV-7 [14] , significantly prolonged the bleeding times when they were intravenously administered at the efficacious antithrombotic doses.
TMV-7 does not cause immune clearance of platelets in FccRIIa transgenic mice
To better understand the effects of these antithrombotics in FccRIIa-mediated thrombocytopenia in vivo, a transgenic mouse line expressing FccRIIa on platelets at levels equivalent to human cells was used [24, 41] . After intravenous injection of the indicated antithrombotics for 5 min (Fig. 6H) , neither wild-type nor FccRIIa transgenic mice showed significant changes in platelet counts. However, between 5 h and 10 h, FccRIIa transgenic mice treated with eptifibatide, TMV-2 and rhodostomin showed severe thrombocytopenia, with platelet counts in the 300 000 lL À1 range (48.5% of control), 500 000 lL À1 range (65.4% of control), and 600 000 lL À1 range (76.5% of control), respectively. However, eptifibatide, rhodostomin and TMV-2 treatment resulted in a gradual recovery in platelet counts, measured after 24 h. In contrast, TMV-7-injected wild-type and FccRIIa transgenic mice showed no significant changes in platelet counts, indicating that TMV-7 has less tendency to cause FccRIIa-mediated immune clearance of platelets. 
TMV-7 does not affect human platelet function in ROTEM
To mimic bleeding during intravascular/surgical processes, ROTEM, a point-of-care method that is mainly utilized in the perioperative scenario [42, 43] , was used to evaluate physiologic platelet function in human whole blood containing these antithrombotics. As shown in Fig. 7A-D , CT represented the initial coagulation rate, clot formation time (CFT) and a-angle showed good correlations with activated partial thromboplastin time/prothrombin time, and maximum clot firmness (MCF) was correlated with platelet count. Our previous study showed that rhodostomin concentration-dependently decreased the a-angle and MCF, and prolonged CT and CFT [14] . Here, TMV-2 and eptifibatide ( Fig. 7A-D) showed a similar effect on physiologic platelet function in ROTEM, leading to a hypocoagulable state, whereas TMV-7 did not affect any coagulation index as compared with the control group, indicating that TMV-7 has less influence on physiologic hemostasis.
TMV-7 has less influence on plasma recalcification time
The anticoagulant properties of TMV-2 and TMV-7 were further assessed with RT assays performed on healthy human plasma, and compared with those of eptifibatide (Fig. 7E, F) . The normal RT value was~200 s. TMV-2 and eptifibatide prolonged RT in a concentration-dependent manner, whereas TMV-7 did not affect RT, consistent with its minimal effect on the coagulation index.
TMV-7 has less influence on clot retraction
Clot retraction is a joint function of platelet activation to form a platelet plug and coagulation cascade in physiologic hemostasis [22, 44] , so we assessed the effects of TMV-2 and TMV-7 on clot retraction in human PRP. As shown in Fig. 7G ,H, TMV-2 inhibited thrombin-induced clot retraction, whereas TMV-7 had less effect, indicating that TMV-7 has a minimal effect on normal physiologic hemostasis.
TMV-7 does not affect physiologic hemostasis of human whole blood in PFA-100
We further confirmed the hemostatic effects of TMV-2, TMV-7 and eptifibatide by using PFA-100 (Fig. 7I) , which is considered to be an 'in vitro bleeding time' assay [45, 46] . Eptifibatide prolongs closure time at the concentrations (1.25 lM) achieved in clinical practice. In contrast to TMV-2, TMV-7 did not prolong closure time with ADP stimulation at a high concentration (3 lg mL À1 ).
TMV-7 as a selective inhibitor of G a13 binding to the b 3 cytoplasmic domain
Recent studies on the mechanisms of a IIb b 3 signaling suggest that selectively targeting outside-in signaling may prevent thrombosis without causing bleeding [17, 47] . Thus, we further investigated the effects of these a IIb b 3 antagonists on the mutually exclusive binding of the cytosolic proteins talin and G a13 to the b 3 cytoplasmic domain, and found that TMV-7 selectively inhibited G a13 binding to the b 3 domain without affecting talin binding to b 3 (Fig. S4) or perturbing talin-driven hemostatic processes, i.e. clot retraction (Fig. 7G,H ) and agonist-induced PAC1 binding to a IIb b 3 (unpublished data), thus showing high antithrombotic efficacy while maintaining hemostasis in animal models.
Structure-activity relationships for TMV-7 derivatives
We further mutated the sequence of TMV-7 in its linker domain, RGD domain, or C-terminal domain, and evaluated which amino acid substitution in TMV-7 correlates with high bleeding risk (Table S1 ). We mutated the RGD domain from ARGDNP to AKGDWN or AKGDFP, and found that these derivatives showed a three-fold to six-fold lower safety index than TMV-7. In contrast, mutating KKKR to IEEG in the linker domain increased the safety index, but resulted in four-fold to 10-fold lower potency in inhibiting platelet aggregation. Thus, the TMV-7 (0.25 µg g -1 )
structure-function relationship of TMV-7 is being explored to optimize the balance between potent antithrombotic effects and bleeding side effects.
The in vivo half-life of TMV-2 and TMV-7 in inhibiting platelet aggregation
As TMV-2 and TMV-7 were given intravenously, we tested their pharmacokinetic profiles by using a functional half-life (t 1/2 ) assay (Fig. 8) . After intravenous administration of agents for 10 min, their antiplatelet activity reached its maximum (100% inhibition) in mice. The inhibitory effect of eptifibatide quickly decayed over a period of 10 h (t 1/2 = 2.54 AE 0.24 h), whereas the inhibitory effects of TMV-2 and TMV-7 were sustained for > 20 h (t 1/2 = 8.65 AE 0.27 h and t 1/2 = 9.38 AE 0.28 h, respectively), indicating that the pharmacokinetic profiles of TMV-2 and TMV-7 are similar to each other, and higher than that of eptifibatide.
Discussion
The eptifibatide-dependent or tirofiban-dependent antibodies are known to recognize LIBSs in a drug-dependent manner [8, 48, 49] . Although it is known that eptifibatidedependent and tirofiban-dependent antibodies are capable of inducing platelet activation leading to occasional thrombocytopenia [39] , the exact mechanism by which such antibodies activate platelets is poorly explored.
Integrin a IIb b 3 antagonists are not only potent antithrombotics, but also have significant side effects. RGD-containing a IIb b 3 antagonists inhibit platelet aggregation and thrombosis formation through blockade of the RGD-binding site of a IIb b 3 . Here, we investigated the relationship between the binding epitopes of disintegrins and their tendency to cause FccRIIa-mediated thrombocytopenia. In this study, we classified disintegrins into two groups according to their binding sites on a IIb b 3 , namely bA of the b 3 domain and the b-propeller of a IIb domain. The purified small-mass RGD-containing a IIb b 3 antagonists rhodostomin and TMV-2 bound to an epitope of a IIb b 3 close to the bA domain, whereas TMV-7 bound to the a IIb b-propeller domain, with the advantage that TMV-7 neither primed a IIb b 3 to adopt a high-affinity ligand binding state (Fig. 4A-C) nor caused a conformational change of a IIb b 3 identified with the LIBS antibody AP5 (Fig. 4D) , demonstrating that TMV-7, with a minimal effect on integrin conformation, seems to be incapable of inducing the production of DDAbs. Thus, in contrast to bA-specific a IIb b 3 blockers (i.e. rhodostomin and TMV-2), TMV-7 binding to a IIb b 3 neither recruits AP2 (Fig. 4F,G) for engagement of the bA domain and FccRIIa, nor induces FccRIIa-mediated thrombocytopenia in FccRIIa transgenic mice [8, 11] . According to these results, the bleeding tendency in mice and humans may be reduced with b-propeller-specific blockers in comparison with bA-specific a IIb b 3 blockers.
The rationale for using mAb AP2 as a platform to evaluate the adverse reaction of thrombocytopenia upon administration of a IIb b 3 antagonists instead of the intrinsic DDAbs is as follows: (i) the incidence of thrombocytopenia in the clinic after administration of a IIb b 3 antagonists is low, at approximately 0.1-2.0%, so the availability of these DDAbs is limited, and their capabilities in inducing platelet activation are variable; and (ii) our study indicates that AP2 shows very good sensitivity and reproducibility (4 lg mL
À1
) in predicting the ability of a IIb b 3 antagonists or RGD mimetics to cause FccRIIamediated platelet activation in vitro.
We also found a positive causal effect of eptifibatide and bA-specific a IIb b 3 blockers (i.e. TMV-2 and rhodostomin) in causing clearance of platelets in FccRIIa transgenic mice, in contrast to TMV-7 (Fig. 6H) . Furthermore, in contrast to bA-specific a IIb b 3 blockers, TMV-7 had minor effects on human plasma RT (Fig. 7E,  F) and thrombin-induced clot retraction (Fig. 7G,H) . In human whole blood, TMV-7 did not cause a defect in physiologic hemostasis in ROTEM (Fig. 7A-D) and PFA (Fig. 7I) assays. Thus, although these a IIb b 3 antagonists potently inhibited occlusive thrombosis in vivo, TMV-7 did not prolong bleeding time.
In line with these observations, the RGD-containing disintegrin TMV-7, which has a binding motif for the a IIb b-propeller, minimally affects conformational change, and thus efficaciously prevents pathologic thrombosis without affecting physiologic hemostasis. This study indicates that the structural differences among rhodostomin, TMV-2, and TMV-7 and its mutants, especially the amino residues of the RGD loop and the C-terminals and their molecular interactions with a IIb b 3 , may provide valuable information for the development of potential antithrombotic agents with minimal thrombocytopenia and bleeding side effects. index, tail-bleeding time and molecular weight among the clinical antithrombotic agent eptifibatide, TMV-2, TMV-7, and TMV-7 mutants. Fig. S1 . Purification of TMV-2 and TMV-7 from Trimeresurus mucrosquamatus snake venom. Fig. S2 . The top-down MS/MS spectra for TMV-2 and TMV-7. 
